185 related articles for article (PubMed ID: 19509354)
21. Design of clinical trials of radiation combined with antiangiogenic therapy.
Senan S; Smit EF
Oncologist; 2007 Apr; 12(4):465-77. PubMed ID: 17470689
[TBL] [Abstract][Full Text] [Related]
22. The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB; Dahut WL
Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
[TBL] [Abstract][Full Text] [Related]
23. Tumor endothelial cells join the resistance.
Dudley AC; Klagsbrun M
Clin Cancer Res; 2009 Aug; 15(15):4787-9. PubMed ID: 19638456
[TBL] [Abstract][Full Text] [Related]
24. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
25. Drug essentials. Small molecule multitargeted TKI therapy.
Wilkes GM
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):47-8. PubMed ID: 19856581
[No Abstract] [Full Text] [Related]
26. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
27. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Podar K; Anderson KC
Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
[TBL] [Abstract][Full Text] [Related]
28. Update on angiogenesis inhibitors.
Zakarija A; Soff G
Curr Opin Oncol; 2005 Nov; 17(6):578-83. PubMed ID: 16224236
[TBL] [Abstract][Full Text] [Related]
29. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
[TBL] [Abstract][Full Text] [Related]
30. [Targeted therapies and their indications in solid neoplasias].
Dreyer C; Raymond E; Faivre S
Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
[TBL] [Abstract][Full Text] [Related]
31. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Quesada AR; Medina MA; Alba E
Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
[TBL] [Abstract][Full Text] [Related]
32. Cancer: The nuances of therapy.
Ellis LM; Reardon DA
Nature; 2009 Mar; 458(7236):290-2. PubMed ID: 19295595
[No Abstract] [Full Text] [Related]
33. [Anti-angiogenesis and molecular targeted therapies].
Miyanaga A; Gemma A
Nihon Rinsho; 2015 Aug; 73(8):1336-41. PubMed ID: 26281687
[TBL] [Abstract][Full Text] [Related]
34. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
35. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
36. Multi-kinase inhibitors create buzz at ASCO.
Branca MA
Nat Biotechnol; 2005 Jun; 23(6):639. PubMed ID: 15940222
[No Abstract] [Full Text] [Related]
37. Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Arbiser JL
J Invest Dermatol; 2009 Mar; 129(3):538-40. PubMed ID: 19209155
[TBL] [Abstract][Full Text] [Related]
38. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
39. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Rini BI
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab, sunitinib: osteonecrosis of the jaw.
Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
